Neupro and Mirabegron drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Neupro (rotigotine) and Mirabegron (mirabegron). Common drug interactions include heart rate irregular among females and diarrhoea among males.

The phase IV clinical study analyzes what interactions people have when they take Neupro and Mirabegron. It is created by eHealthMe based on reports of 40 people who take the same drugs from the FDA, and is updated regularly.

What is Neupro?

Neupro has active ingredients of rotigotine. It is often used in parkinson's disease. eHealthMe is studying from 11,393 Neupro users. Check the latest studies of Neupro.

What is Mirabegron?

Mirabegron has active ingredients of mirabegron. It is often used in urge incontinence. eHealthMe is studying from 5,414 Mirabegron users. Check the latest studies of Mirabegron.



On Jul, 13, 2026

40 people who take Neupro and Mirabegron together, and have interactions are studied.

Neupro and Mirabegron drug interactions.

What are the common drug interactions of Neupro and Mirabegron, by gender? *:

female:

  1. Heart rate irregular
  2. Hemiparesis (weakness on one side of the body)
  3. Hypophagia (reduced food intake)
  4. Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development)
  5. Initial insomnia (feeling of inadequate or poor-quality sleep)
  6. Mitral valve incompetence (inefficient heart valve)
  7. Mobility decreased (ability to move is reduced)
  8. Nail bed inflammation (infection of nail bed)
  9. Onycholysis (detachment of the nail from the nail bed)
  10. Overdose

male:

  1. Diarrhoea
  2. Device dislocation
  3. C-reactive protein increased
  4. Chills (felling of cold)
  5. Colitis (inflammation of colon)
  6. Gamma-glutamyltransferase increased
  7. General physical health deterioration (weak health status)
  8. Lymphocyte count decreased
  9. Neutrophil count increased (excess than normal number of neutrophil a type of blood cell)
  10. Pruritus (severe itching of the skin)

What are the common drug interactions of Neupro and Mirabegron, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Folate deficiency (lack of folic acid)
  2. Infusion related reaction
  3. Iron deficiency anaemia
  4. Urinary tract infection
  5. Influenza
  6. Lymphocyte count decreased

40-49:

  1. Confusional state
  2. Hallucination, visual (seeing things that aren't there)

50-59:

  1. Amnesia (deficit in memory caused by brain damage, disease, or psychological trauma)
  2. Asthenia (weakness)
  3. Constipation
  4. Dizziness
  5. Fall
  6. Headache (pain in head)
  7. Hypoaesthesia (reduced sense of touch or sensation)
  8. Initial insomnia (feeling of inadequate or poor-quality sleep)
  9. Memory impairment
  10. Muscle spasms (muscle contraction)

60+:

  1. Dyskinesia (abnormality or impairment of voluntary movement)
  2. On and off phenomenon
  3. Aspartate aminotransferase decreased
  4. Aspartate aminotransferase increased
  5. Blood alkaline phosphatase increased
  6. Blood creatinine increased
  7. Blood lactate dehydrogenase increased
  8. C-reactive protein increased
  9. Chills (felling of cold)
  10. Colitis (inflammation of colon)

What are the existing conditions these people have? *

  1. Rickets (softening of bones): 7 people, 17.50%
  2. Restless Leg Syndrome (a powerful urge to move your legs): 6 people, 15.00%
  3. Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 5 people, 12.50%
  4. Neuralgia (pain in one or more nerves): 4 people, 10.00%
  5. Migraine (headache): 4 people, 10.00%
  6. Iron Deficiency: 4 people, 10.00%
  7. High Blood Pressure: 3 people, 7.50%
  8. Pollakiuria (abnormally frequent passage of relatively small quantities or urine): 2 people, 5.00%
  9. Osteoporosis (bones weak and more likely to break): 2 people, 5.00%
  10. Malignant Neoplasm Progression (cancer tumour came back): 2 people, 5.00%

* Approximation only. Some reports may have incomplete information.

Do you take Neupro and Mirabegron?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Neupro and Mirabegron:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Neupro:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Mirabegron:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Neupro and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Mirabegron and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on rotigotine and mirabegron (the active ingredients of Neupro and Mirabegron, respectively), and Neupro and Mirabegron (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: